155 related articles for article (PubMed ID: 33421352)
1. Interferon-γ and IL-5 associated cell-mediated immune responses to HPV16 E2 and E6 distinguish between persistent oral HPV16 infections and noninfected mucosa.
Paaso A; Koskimaa HM; Welters MJP; Kero K; Rautava J; Syrjänen K; van der Burg SH; Syrjänen S
Clin Exp Dent Res; 2021 Oct; 7(5):903-913. PubMed ID: 33421352
[TBL] [Abstract][Full Text] [Related]
2. Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years.
Paaso A; Koskimaa HM; Welters MJ; Grénman S; Syrjänen K; van der Burg SH; Syrjänen S
J Transl Med; 2015 May; 13():163. PubMed ID: 25990808
[TBL] [Abstract][Full Text] [Related]
3. The presence of human papillomavirus (HPV) in placenta and/or cord blood might result in Th2 polarization.
Koskimaa HM; Paaso A; Welters MJP; Grénman S; Syrjänen K; van der Burg SH; Syrjänen S
Eur J Clin Microbiol Infect Dis; 2017 Aug; 36(8):1491-1503. PubMed ID: 28324192
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6.
de Jong A; van Poelgeest MI; van der Hulst JM; Drijfhout JW; Fleuren GJ; Melief CJ; Kenter G; Offringa R; van der Burg SH
Cancer Res; 2004 Aug; 64(15):5449-55. PubMed ID: 15289354
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish Family HPV cohort.
Koskimaa HM; Paaso AE; Welters MJ; Grénman SE; Syrjänen KJ; van der Burg SH; Syrjänen SM
J Transl Med; 2014 Feb; 12():44. PubMed ID: 24524328
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus 16-specific cell-mediated immunity in children born to mothers with incident cervical intraepithelial neoplasia (CIN) and to those constantly HPV negative.
Koskimaa HM; Paaso A; Welters MJ; Grénman S; Syrjänen K; van der Burg SH; Syrjänen S
J Transl Med; 2015 Nov; 13():370. PubMed ID: 26608420
[TBL] [Abstract][Full Text] [Related]
7. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
[TBL] [Abstract][Full Text] [Related]
8. Human Papillomavirus (HPV) 16 E6 seropositivity is elevated in subjects with oral HPV16 infection.
Zhang Y; Waterboer T; Pawlita M; Sugar E; Minkoff H; Cranston RD; Wiley D; Burk R; Reddy S; Margolick J; Strickler H; Weber K; Gillison M; D'Souza G
Cancer Epidemiol; 2016 Aug; 43():30-4. PubMed ID: 27344614
[TBL] [Abstract][Full Text] [Related]
9. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection.
Farhat S; Nakagawa M; Moscicki AB
Int J Gynecol Cancer; 2009 May; 19(4):508-12. PubMed ID: 19509544
[TBL] [Abstract][Full Text] [Related]
10. CD8
Masterson L; Lechner M; Loewenbein S; Mohammed H; Davies-Husband C; Fenton T; Sudhoff H; Jani P; Goon P; Sterling J
Eur J Cancer; 2016 Nov; 67():141-151. PubMed ID: 27669501
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus does not have a causal role in colorectal carcinogenesis.
Lorenzon L; Mazzetta F; Pilozzi E; Uggeri G; Torrisi MR; Ferri M; Ziparo V; French D
World J Gastroenterol; 2015 Jan; 21(1):342-50. PubMed ID: 25574110
[TBL] [Abstract][Full Text] [Related]
12. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence.
Lang Kuhs KA; Kreimer AR; Trivedi S; Holzinger D; Pawlita M; Pfeiffer RM; Gibson SP; Schmitt NC; Hildesheim A; Waterboer T; Ferris RL
Cancer; 2017 Nov; 123(22):4382-4390. PubMed ID: 28950407
[TBL] [Abstract][Full Text] [Related]
14. Prevalence, genotype distribution and persistence of human papillomavirus in oral mucosa of women: a six-year follow-up study.
Rautava J; Willberg J; Louvanto K; Wideman L; Syrjänen K; Grénman S; Syrjänen S
PLoS One; 2012; 7(8):e42171. PubMed ID: 22952591
[TBL] [Abstract][Full Text] [Related]
15. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment.
van Poelgeest MI; van Seters M; van Beurden M; Kwappenberg KM; Heijmans-Antonissen C; Drijfhout JW; Melief CJ; Kenter GG; Helmerhorst TJ; Offringa R; van der Burg SH
Clin Cancer Res; 2005 Jul; 11(14):5273-80. PubMed ID: 16033846
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study.
Anantharaman D; Gheit T; Waterboer T; Abedi-Ardekani B; Carreira C; McKay-Chopin S; Gaborieau V; Marron M; Lagiou P; Ahrens W; Holcátová I; Merletti F; Kjaerheim K; Talamini R; Simonato L; Castellsague X; Macfarlane TV; Biggs AM; Thakker N; Znaor A; Thomson P; Canova C; Conway DI; Healy CM; Tommasino M; Pawlita M; Brennan P
J Natl Cancer Inst; 2013 Apr; 105(8):536-45. PubMed ID: 23503618
[TBL] [Abstract][Full Text] [Related]
17. Anti-HPV16 E2 protein T-cell responses and viral control in women with usual vulvar intraepithelial neoplasia and their healthy partners.
Jacobelli S; Sanaa F; Moyal-Barracco M; Pelisse M; Berville S; Villefroy P; North MO; Figueiredo S; Charmeteau B; Clerici T; Plantier F; Arnold F; Touzé A; Dupin N; Avril MF; Guillet JG; Cheynier R; Bourgault-Villada I
PLoS One; 2012; 7(5):e36651. PubMed ID: 22590583
[TBL] [Abstract][Full Text] [Related]
18. Physical state and copy numbers of HPV16 in oral asymptomatic infections that persisted or cleared during the 6-year follow-up.
Lorenzi A; Rautava J; Kero K; Syrjänen K; Longatto-Filho A; Grenman S; Syrjänen S
J Gen Virol; 2017 Apr; 98(4):681-689. PubMed ID: 28100295
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus 16 (HPV16) and HPV52 E6-specific immunity in HIV-infected adults on combination antiretroviral therapy.
Leng CY; Low HC; Chua LL; Chong ML; Sulaiman H; Azwa I; Roberts JM; Kamarulzaman A; Rajasuriar R; Woo YL
HIV Med; 2017 May; 18(5):321-331. PubMed ID: 27649852
[TBL] [Abstract][Full Text] [Related]
20. Depletion of Human Papilloma Virus E6- and E7-Oncoprotein-Specific T-Cell Responses in Women Living With HIV.
Mbuya W; Held K; Mcharo RD; Haule A; Mhizde J; Mnkai J; Mahenge A; Mwakatima M; Sembo M; Mwalongo W; Agrea P; Hoelscher M; Maboko L; Saathoff E; Geisenberger O; Rwegoshora F; Torres L; Koup RA; Kroidl A; Chachage M; Geldmacher C
Front Immunol; 2021; 12():742861. PubMed ID: 34759925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
